Karyopharm Therapeutics Backs 2024 View of Rev $140M-$160M >KPTI
Karyopharm Therapeutics Backs 2024 View of Rev $140M-$160M >KPTI
Karyopharm Therapeutics支持2024年修订的1.4亿美元至1.6亿美元的观点 >KPTI
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册